Michelle Shayne
Concepts (111)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of publications
|
Most recent publication
|
Publications by all authors
|
Why?
|
|---|
Breast Neoplasms | 6 | 2006 | 185 |
Why?
|
Neutropenia | 4 | 2006 | 42 |
Why?
|
Neoplasms | 3 | 2007 | 239 |
Why?
|
Antineoplastic Agents | 4 | 2007 | 190 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2007 | 121 |
Why?
|
Granulocyte Colony-Stimulating Factor | 3 | 2006 | 34 |
Why?
|
Hematopoietic Cell Growth Factors | 1 | 2011 | 9 |
Why?
|
Hematologic Diseases | 1 | 2009 | 23 |
Why?
|
Vitiligo | 1 | 2008 | 3 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2008 | 24 |
Why?
|
Anthracyclines | 1 | 2006 | 7 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2007 | 64 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2006 | 35 |
Why?
|
Patient Selection | 2 | 2006 | 155 |
Why?
|
Aging | 1 | 2011 | 275 |
Why?
|
Drug Administration Schedule | 2 | 2006 | 191 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2007 | 431 |
Why?
|
Humans | 12 | 2006 | 1856 |
Why?
|
Aged | 5 | 2006 | 988 |
Why?
|
Aged, 80 and over | 3 | 2007 | 599 |
Why?
|
Age Factors | 2 | 2006 | 480 |
Why?
|
Female | 8 | 2006 | 1643 |
Why?
|
Humanities | 1 | 2010 | 6 |
Why?
|
HSP27 Heat-Shock Proteins | 1 | 2011 | 14 |
Why?
|
Receptors, Progesterone | 1 | 2010 | 28 |
Why?
|
Medical Oncology | 1 | 2010 | 28 |
Why?
|
Acupressure | 1 | 2010 | 8 |
Why?
|
Taxoids | 1 | 2010 | 12 |
Why?
|
Deoxycytidine | 1 | 2010 | 20 |
Why?
|
Stomach Neoplasms | 1 | 2010 | 28 |
Why?
|
Fluorouracil | 1 | 2010 | 49 |
Why?
|
Teaching | 1 | 2010 | 89 |
Why?
|
Neoplasm Staging | 2 | 2007 | 125 |
Why?
|
Risk Factors | 2 | 2006 | 555 |
Why?
|
Education, Medical, Graduate | 1 | 2010 | 70 |
Why?
|
Anemia | 1 | 2009 | 60 |
Why?
|
Thrombocytopenia | 1 | 2009 | 46 |
Why?
|
Nausea | 1 | 2010 | 34 |
Why?
|
Neoadjuvant Therapy | 1 | 2008 | 19 |
Why?
|
Macrophages | 1 | 2011 | 148 |
Why?
|
Esophageal Neoplasms | 1 | 2010 | 37 |
Why?
|
Tumor Markers, Biological | 1 | 2010 | 112 |
Why?
|
Doxorubicin | 1 | 2008 | 60 |
Why?
|
Cyclophosphamide | 1 | 2008 | 82 |
Why?
|
Colony-Stimulating Factors | 1 | 2007 | 13 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2007 | 53 |
Why?
|
Disease-Free Survival | 1 | 2007 | 102 |
Why?
|
Chemokines, CXC | 1 | 2007 | 32 |
Why?
|
Blood Proteins | 1 | 2007 | 71 |
Why?
|
Proteome | 1 | 2007 | 25 |
Why?
|
Body Surface Area | 1 | 2006 | 8 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2006 | 49 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2006 | 55 |
Why?
|
Adenocarcinoma | 1 | 2010 | 167 |
Why?
|
Radiotherapy Dosage | 1 | 2006 | 55 |
Why?
|
Evidence-Based Medicine | 1 | 2007 | 125 |
Why?
|
Multivariate Analysis | 1 | 2007 | 225 |
Why?
|
Myelodysplastic Syndromes | 1 | 2007 | 27 |
Why?
|
Logistic Models | 1 | 2007 | 251 |
Why?
|
Odds Ratio | 1 | 2006 | 157 |
Why?
|
Health Care Surveys | 1 | 2006 | 91 |
Why?
|
Comorbidity | 1 | 2006 | 190 |
Why?
|
Lymph Nodes | 1 | 2006 | 106 |
Why?
|
Kidney Diseases | 1 | 2006 | 90 |
Why?
|
Practice Guidelines as Topic | 1 | 2007 | 174 |
Why?
|
Recombinant Proteins | 1 | 2007 | 290 |
Why?
|
Biological Markers | 1 | 2007 | 262 |
Why?
|
Retrospective Studies | 2 | 2006 | 653 |
Why?
|
Severity of Illness Index | 1 | 2007 | 358 |
Why?
|
Prospective Studies | 1 | 2007 | 545 |
Why?
|
Middle Aged | 4 | 2006 | 1161 |
Why?
|
Risk Assessment | 1 | 2006 | 324 |
Why?
|
Adult | 3 | 2008 | 1317 |
Why?
|
Treatment Outcome | 1 | 2006 | 661 |
Why?
|
United States | 1 | 2006 | 604 |
Why?
|
Male | 2 | 2007 | 1553 |
Why?
|
Tumor Microenvironment | 1 | 2011 | 10 |
Why?
|
Literature | 1 | 2010 | 6 |
Why?
|
Writing | 1 | 2010 | 14 |
Why?
|
Narration | 1 | 2010 | 18 |
Why?
|
Feedback | 1 | 2010 | 54 |
Why?
|
Suggestion | 1 | 2010 | 7 |
Why?
|
Relaxation Therapy | 1 | 2010 | 12 |
Why?
|
Outpatients | 1 | 2010 | 29 |
Why?
|
Fellowships and Scholarships | 1 | 2010 | 34 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2010 | 29 |
Why?
|
Receptor, erbB-2 | 1 | 2010 | 25 |
Why?
|
Immune Tolerance | 1 | 2011 | 72 |
Why?
|
Neovascularization, Pathologic | 1 | 2011 | 64 |
Why?
|
Program Evaluation | 1 | 2010 | 115 |
Why?
|
Vomiting | 1 | 2010 | 45 |
Why?
|
Receptors, Estrogen | 1 | 2010 | 44 |
Why?
|
Pilot Projects | 1 | 2010 | 264 |
Why?
|
Monocytes | 1 | 2011 | 124 |
Why?
|
Curriculum | 1 | 2010 | 127 |
Why?
|
Patient Education as Topic | 1 | 2010 | 128 |
Why?
|
Disease Progression | 1 | 2011 | 244 |
Why?
|
Case-Control Studies | 1 | 2011 | 283 |
Why?
|
Cell Line, Tumor | 1 | 2011 | 208 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2010 | 126 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2010 | 118 |
Why?
|
Survival Analysis | 1 | 2010 | 205 |
Why?
|
Prognosis | 1 | 2010 | 388 |
Why?
|
Internship and Residency | 1 | 2010 | 175 |
Why?
|
T-Lymphocytes | 1 | 2011 | 182 |
Why?
|
Mass Spectrometry | 1 | 2007 | 57 |
Why?
|
Immunohistochemistry | 1 | 2010 | 355 |
Why?
|
New York | 1 | 2010 | 422 |
Why?
|
Young Adult | 1 | 2010 | 380 |
Why?
|
Questionnaires | 1 | 2010 | 360 |
Why?
|
Cell Differentiation | 1 | 2011 | 262 |
Why?
|
